https://www.selleckchem.com/pr....oducts/pf-06650833.h
001), drainage time (P 0.001), days of hospitalization (P 0.001) and VAS at discharge (P = 0.042) were lower in the VATS group. The overall survival and disease-free survival were equivalent for the two techniques on long-term follow-up. VATS lobectomy represents a valid therapeutic option in patients affected by non-small-cell lung cancer after neoadjuvant chemotherapy. The VATS approach in our experience seems to be superior in terms of the perioperative outcomes, while maintaining oncological efficacy. VATS lobectomy re
Beğen
Yorum Yap
Paylaş
